Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer

References

• MoyerJDBarbacciEGIwataKKInduction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinaseCancer Res199757483848489354447
   PubMed Web of Science ®Google Scholar
• PollackVASavageDMBakerDAInhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic miceJ Pharmacol Exp Ther199929173974810525095
   PubMed Web of Science ®Google Scholar
• DanceyJSausvilleEAIssues and progress with protein kinase inhibitors for cancer treatmentNat Rev Drug Discov2003229631312669029
   PubMed Web of Science ®Google Scholar
• SalomonDSBrandtRCiardielloFNormannoNEpidermal growth factor-related peptides and their receptors in human malignanciesCrit Rev Oncol Hematol1995191832327612182
   PubMed Web of Science ®Google Scholar
• EPARs for authorised medicinal products for human use, EMEA wwwemaeuropaeu/humandocs/Humans/EPAR/tarceva/tarcevahtm Accessed March 2, 2010.
   Google Scholar
• US Food and Drug Administration, FDA www.accessdatafdagov/Scripts/cder/DrugsatFDA/indexcfm?fuseaction=SearchDrugDetails Accessed March 2, 2010.
   Google Scholar
• VincentMDOptimizing the management of advanced non-small-cell lung cancer: a personal viewCurr Oncol20091692119672420
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardECancer statistics, 2008CA Cancer J Clin200858719618287387
   PubMed Web of Science ®Google Scholar
• BunnPAJrKellyKNew chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directionsClin Cancer Res19984108711009607565
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med2002346929811784875
   PubMed Web of Science ®Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol2008263543355118506025
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med20063552542255017167137
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol2009271227123419188680
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet20093731525153119410716
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology Clinical Practice Guidelines Update on Chemotherapy for Stage IV Non-Small Cell Lung Cancer www.ascoorg/guidelines/nsclc. Accessed March 2, 2010.
   Google Scholar
• GatzemeierUPluzanskaASzczesnaAPhase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation TrialJ Clin Oncol2007251545155217442998
   PubMed Web of Science ®Google Scholar
• ShepherdFADanceyJRamlauRProspective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyJ Clin Oncol2000182095210310811675
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med200535312313216014882
   PubMed Web of Science ®Google Scholar
• HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol2004221589159715117980
   PubMed Web of Science ®Google Scholar
• CiuleanuTBrodowiczTZielinskiCMaintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyLancet20093741432144019767093
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A2004101133061331115329413
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience20043041497150015118125
   PubMed Web of Science ®Google Scholar
• GazdarAFActivating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene200928Suppl 1S24S3119680293
   PubMed Web of Science ®Google Scholar
• BazleyLAGullickWJThe epidermal growth factor receptor familyEndocr Relat Cancer200512Suppl 1S17S2716113093
   PubMed Web of Science ®Google Scholar
• KumarAPetriETHalmosBBoggonTJStructure and clinical relevance of the epidermal growth factor receptor in human cancerJ Clin Oncol2008261742175118375904
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGEGFR antagonists in cancer treatmentN Engl J Med20083581160117418337605
   PubMed Web of Science ®Google Scholar
• GazdarAFMinnaJDDeregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loopsCancer Prev Res (Phila Pa)20081156160
   Web of Science ®Google Scholar
• EkstrandAJSugawaNJamesCDCollinsVPAmplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tailsProc Natl Acad Sci U S A199289430943131584765
   PubMed Web of Science ®Google Scholar
• ShigematsuHGazdarAFSomatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInt J Cancer200611825726216231326
   PubMed Web of Science ®Google Scholar
• MitsudomiTKosakaTYatabeYBiological and clinical implications of EGFR mutations in lung cancerInt J Clin Oncol20061119019816850125
   PubMed Web of Science ®Google Scholar
• TanakaTMatsuokaMSutaniAFrequency of and variables associated with the EGFR mutation and its subtypesInt J Cancer201012665165519609951
   PubMed Web of Science ®Google Scholar
• SordellaRBellDWHaberDASettlemanJGefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathwaysScience20043051163116715284455
   PubMed Web of Science ®Google Scholar
• AraoTFukumotoHTakedaMTamuraTSaijoNNishioKSmall in-frame deletion in the epidermal growth factor receptor as a target for ZD6474Cancer Res2004649101910415604279
   PubMed Web of Science ®Google Scholar
• GreulichHChenTHFengWOncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsPLoS Med20052e31316187797
   PubMed Web of Science ®Google Scholar
• JannePAJohnsonBEEffect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitorsClin Cancer Res2006124416s4420s16857820
   PubMed Web of Science ®Google Scholar
• MukoharaTEngelmanJAHannaNHDifferential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutationsJ Natl Cancer Inst2005971185119416106023
   PubMed Web of Science ®Google Scholar
• JackmanDMYeapBYSequistLVExon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinibClin Cancer Res2006123908391416818686
   PubMed Web of Science ®Google Scholar
• JiangJGreulichHJannePASellersWRMeyersonMGriffinJDEpidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progressionCancer Res2005658968897416204070
   PubMed Web of Science ®Google Scholar
• HammermanPSJannePAJohnsonBEResistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerClin Cancer Res2009157502750920008850
   PubMed Web of Science ®Google Scholar
• YunCHBoggonTJLiYStructures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivityCancer Cell20071121722717349580
   PubMed Web of Science ®Google Scholar
• RukazenkovYSpeakeGMarshallGEpidermal growth factor receptor tyrosine kinase inhibitors: similar but different?Anticancer Drugs20092085686619657272
   PubMed Web of Science ®Google Scholar
• SpeakeGAndertonJAchesonKA pharmacological comparison of gefitinib and erlotinib97th American Association of Cancer Research Annual MeetingWashington, DC, USA2006 poster 3784.
   Google Scholar
• YuzaYGlattKAJiangJAllele-dependent variation in the relative cellular potency of distinct EGFR inhibitorsCancer Biol Ther2007666166717495523
   PubMed Web of Science ®Google Scholar
• SequistLVJoshiVAJannePAEpidermal growth factor receptor mutation testing in the care of lung cancer patientsClin Cancer Res2006124403s4408s16857818
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med200936195896719692684
   PubMed Web of Science ®Google Scholar
• JackmanDMMillerVACioffrediLAImpact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsClin Cancer Res2009155267527319671843
   PubMed Web of Science ®Google Scholar
• SequistLVMartinsRGSpigelDFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJ Clin Oncol2008262442244918458038
   PubMed Web of Science ®Google Scholar
• Paz-AresLSoulieresDMelezinekIClinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysisJ Cell Mol Med2009128 [Epub ahead of print]
   Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• InoueAKobayashiKUsuiKFirst-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapyJ Clin Oncol2009271394140019224850
   PubMed Web of Science ®Google Scholar
• MoritaSOkamotoIKobayashiKCombined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutationsClin Cancer Res2009154493449819531624
   PubMed Web of Science ®Google Scholar
• RosellRViteriSMolinaMABenllochSTaronMEpidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancerCurr Opin Oncol20092211212019949333
   PubMed Web of Science ®Google Scholar
• Phase III study (Tarceva®) vs chemotherapy to treat advanced nonsmall cell lung cancer (NSCLC) in patients with mutations in the TK domain of EGFR (NCT00446225) http://clinicaltrialsgov/. Accessed March 2, 2010.
   Google Scholar
• Erlotinib versus gemcitabine/carboplatin in chemo-naive stage IIIB/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) exon 19 or 21 mutation (ML20981)(NCT00874419) http://clinicaltrialsgov/ Accessed March 2, 2010.
   Google Scholar
• ClarkGMZborowskiDMSantabarbaraPSmoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21Clin Lung Cancer2006738939416800964
   PubMed Web of Science ®Google Scholar
• Pemetrexed or erlotinib as second-line therapy in treating patients with advanced non-small cell lung cancer (NCCTG-N0723) http://clinicaltrialsgov/. Accessed March 2, 2010.
   Google Scholar
• von PlessenCBergmanBAndresenOPalliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancerBr J Cancer20069596697317047644
   PubMed Web of Science ®Google Scholar
• SocinskiMASchellMJPetermanAPhase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancerJ Clin Oncol2002201335134311870177
   PubMed Web of Science ®Google Scholar
• BuccheriGFFerrignoDCurcioAVolaFRossoAContinuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective studyCancer1989634284322536288
   PubMed Web of Science ®Google Scholar
• BrodowiczTKrzakowskiMZwitterMCisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trialLung Cancer20065215516316569462
   PubMed Web of Science ®Google Scholar
• ParkJOKimSWAhnJSPhase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancerJ Clin Oncol2007255233523918024869
   PubMed Web of Science ®Google Scholar
• SmithIEO’BrienMETalbotDCDuration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatinJ Clin Oncol2001191336134311230476
   PubMed Web of Science ®Google Scholar
• SoonYYStocklerMRAskieLMBoyerMJDuration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trialsJ Clin Oncol2009273277328319470938
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol2005235892589916043829
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1J Clin Oncol20042277778414990632
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2J Clin Oncol20042278579414990633
   PubMed Web of Science ®Google Scholar
• MokTSWuYLYuCJRandomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancerJ Clin Oncol2009275080508719738125
   PubMed Web of Science ®Google Scholar
• FidiasPMDakhilSRLyssAPPhase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancerJ Clin Oncol20092759159819075278
   PubMed Web of Science ®Google Scholar
• MokTSRamalingamSSMaintenance therapy in nonsmall-cell lung cancer: a new treatment paradigmCancer20091155143515419658185
   PubMed Web of Science ®Google Scholar
• JalalSIAdemuyiwaFOHannaNHThe role of maintenance chemotherapy in advanced nonsmall cell lung cancerCurr Opin Oncol20092111011519532011
   PubMed Web of Science ®Google Scholar
• GoldieJHColdmanAJGudauskasGARationale for the use of alternating non-cross-resistant chemotherapyCancer Treat Rep1982664394497060033
   PubMedGoogle Scholar
• CappuzzoFCiuleanuTStelmakhLSATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLCJ Clin Oncol200927Suppl 158001
   Web of Science ®Google Scholar
• MillerVO’ConnorPSohCA randomized, double-blind, placebo-controlled, phase IIIB trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastasic non-small cell lung cancerJ Clin Oncol200927Suppl 15LBA8002
   Google Scholar
• CappuzzoFCoudertBWierzbickiREfficacy and safety of erlotiniib as first-line maintenance in NSCLC following nonprogression with chemotherapy: results from the phase III SATURN study (abstr A2.1)13th World Conference on On Lung CancerSan Francisco http://www.2009worldlungcancer.org/. Accessed March 2, 2010.
   Google Scholar
• CappuzzoFCoudertBWierzbickiROverall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC). (abstr 22LBA)ECCO 15–34th ESMO Multidisciplinary CongressBerlin http://www.ecco-org.eu/Conferences-and-Events/ECCO-15-ESMO-34/Abstracts-online/page.aspx/1729. Accessed March 2, 2010.
   Google Scholar
• BruggerWKimJHansenOMolecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC (abstr B9.1)13th World Conference on On Lung CancerSan Francisco Available from: http://www.2009worldlungcancer.org/. Accessed March 2, 2010.
   Google Scholar
• GenetechPress Release ATLAS study http://www.genecom/gene/news/press-releases/displaydo?method=detail&id=11827 Accessed March 2, 2010.
   Google Scholar
• JohnsonBMillerVAmlerLBiomarker evaluation in the randomized, double-blind, placebo-controlled, phase IIIb ATLAS trial, comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) (abstr 8LBA)ECCO 15–34th ESMO Multidisciplinary CongressBerlin http://www.eccoorg.eu/Conferences-and-Events/ECCO-15-ESMO-34/Abstracts-online/page.aspx/1729. Accessed March 2, 2010.
   Google Scholar
• CostaDBKobayashiSTenenDGHubermanMSPooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersLung Cancer2007589510317610986
   PubMed Web of Science ®Google Scholar
• EngelmanJASettlemanJAcquired resistance to tyrosine kinase inhibitors during cancer therapyCurr Opin Genet Dev200818737918325754
   PubMed Web of Science ®Google Scholar
• YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci U S A20081052070207518227510
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAEpidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directionsJ Clin Oncol2005232556256815767641
   PubMed Web of Science ®Google Scholar
• BalakMNGongYRielyGJNovel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsClin Cancer Res2006126494650117085664
   PubMed Web of Science ®Google Scholar
• MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med200835936637718596266
   PubMed Web of Science ®Google Scholar
• KwakELSordellaRBellDWIrreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci U S A20051027665767015897464
   PubMed Web of Science ®Google Scholar
• WongKKFracassoPMBukowskiRMA phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsClin Cancer Res2009152552255819318484
   PubMed Web of Science ®Google Scholar
• JannePSchellensHEngelmanJPreliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLCJ Clin Oncol200826Suppl 158027
   Web of Science ®Google Scholar
• MillerVWakeleeHLaraPActivity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trialJ Clin Oncol200826Suppl 158028
   Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience20073161039104317463250
   PubMed Web of Science ®Google Scholar
• GuixMFaberACWangSEAcquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteinsJ Clin Invest20081182609261918568074
   PubMed Web of Science ®Google Scholar
• MorgilloFWooJKKimESHongWKLeeHYHeterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinibCancer Res200666101001011117047074
   PubMed Web of Science ®Google Scholar
• O’ReillyKERojoFSheQBmTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktCancer Res2006661500150816452206
   PubMed Web of Science ®Google Scholar
• RosellRViteriSMolinaMABenllochSTaronMEpidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancerCurr Opin Oncol20102211212019949333
   PubMed Web of Science ®Google Scholar
• JackmanDPaoWRielyGJClinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerJ Clin Oncol20102835736019949011
   PubMed Web of Science ®Google Scholar
• MokTSLiving with imperfectionJ Clin Oncol20102819119219949000
   PubMed Web of Science ®Google Scholar